EnBiotix Overview

  • Year Founded
  • 2010

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 5

Employees

  • Latest Deal Type
  • M&A

EnBiotix General Information

Description

Operator of a bioengineering company specializing in the development of therapies for drug-resistant bacterial infections. The company develops drugs focused on therapies for cystic fibrosis, non-CF bronchiectasis, and non-tuberculosis mycobacterial infections, enabling patients to avail treatment for chronic, recurrent, and life-threatening pulmonary infections.

Contact Information

Website
www.enbiotix.com
Formerly Known As
Anagenix Therapeutics
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • 197 West Springfield Street
  • Boston, MA 02118
  • United States
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Acquirer
Spexis
Vertical(s)
AgTech, Supply Chain Tech, TMT, Life Sciences
Corporate Office
  • 197 West Springfield Street
  • Boston, MA 02118
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

EnBiotix Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
8. Merger/Acquisition 29-Dec-2021 Completed Clinical Trials - General
7. Later Stage VC 05-Apr-2022 Completed Clinical Trials - General
6. Later Stage VC 29-Dec-2021 Completed Clinical Trials - General
5. Later Stage VC (Series B) 26-Sep-2019 Completed Clinical Trials - General
4. Grant 26-May-2016 Completed Clinical Trials - General
3. Later Stage VC (Series A) 12-May-2016 Completed Clinical Trials - General
2. Grant 01-Jan-2016 $264K Completed Startup
1. Accelerator/Incubator Completed Startup
To view EnBiotix’s complete valuation and funding history, request access »

EnBiotix Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series B
Series C
Series A 2,200,000 $0.001000 5% $1.32 $1.32 1x $1.32 12.97%
To view EnBiotix’s complete cap table history, request access »

EnBiotix Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Operator of a bioengineering company specializing in the development of therapies for drug-resistant bacterial infection
Drug Discovery
Boston, MA
5 As of 2021

Lyon, France
 

Aberdeen, United Kingdom
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

EnBiotix Competitors (68)

One of EnBiotix’s 68 competitors is Phaxiam, a Formerly VC-backed company based in Lyon, France.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Phaxiam Formerly VC-backed Lyon, France
NovaBiotics Venture Capital-Backed Aberdeen, United Kingdom
Seres Therapeutics Formerly VC-backed Cambridge, MA
Centrose Venture Capital-Backed Madison, WI
Sorrento Therapeutics Formerly VC-backed San Diego, CA
You’re viewing 5 of 68 competitors. Get the full list »

EnBiotix Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

EnBiotix Former Investors (9)

Investor Name Investor Type Holding Investor Since Participating Rounds
ARCH Venture Partners Venture Capital Minority
Apeiron Holdings Venture Capital Minority
Cystic Fibrosis Foundation Limited Partner
Gates Foundation Not-For-Profit Venture Capital
LabCentral Accelerator/Incubator
You’re viewing 5 of 9 investors. Get the full list »

EnBiotix Acquisitions (1)

EnBiotix’s most recent deal was a Merger/Acquisition with AMP Therapeutics. The deal was made on 03-Nov-2016.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
AMP Therapeutics 03-Nov-2016 Merger/Acquisition Drug Discovery
To view EnBiotix’s complete acquisitions history, request access »

Ready to get started?

Request a free trial

EnBiotix FAQs

  • When was EnBiotix founded?

    EnBiotix was founded in 2010.

  • Where is EnBiotix headquartered?

    EnBiotix is headquartered in Boston, MA.

  • What is the size of EnBiotix?

    EnBiotix has 5 total employees.

  • What industry is EnBiotix in?

    EnBiotix’s primary industry is Drug Discovery.

  • Is EnBiotix a private or public company?

    EnBiotix is a Private company.

  • What is EnBiotix’s current revenue?

    The current revenue for EnBiotix is .

  • How much funding has EnBiotix raised over time?

    EnBiotix has raised $19.6M.

  • Who are EnBiotix’s investors?

    ARCH Venture Partners, Apeiron Holdings, Cystic Fibrosis Foundation, Gates Foundation, and LabCentral are 5 of 9 investors who have invested in EnBiotix.

  • Who are EnBiotix’s competitors?

    Phaxiam, NovaBiotics, Seres Therapeutics, Centrose, and Sorrento Therapeutics are some of the 68 competitors of EnBiotix.

  • When was EnBiotix acquired?

    EnBiotix was acquired on 29-Dec-2021.

  • Who acquired EnBiotix?

    EnBiotix was acquired by Spexis.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process